Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,280 across all filing types
Latest filing 2025-11-28 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
重大信息内部报告制度
Governance Information Classification · 95% confidence The document is titled as an internal reporting system for major information of 广州市香雪制药股份有限公司 (Guangzhou Xiangxue Pharmaceutical Co., Ltd.). It details the procedures, responsibilities, and scope of reporting significant company information internally and for disclosure purposes. The content focuses on governance, internal controls, and compliance with laws and stock exchange rules regarding information disclosure. There are no financial statements, earnings data, or audit results presented. The document is a policy or governance document related to internal reporting and information disclosure management. Therefore, it fits best under Governance Information (CGR). The document length is 7421 characters, which is substantive and not a mere announcement or certification, supporting this classification.
2025-11-28 Chinese
子公司管理制度
Governance Information Classification · 95% confidence The document is titled '子公司管理制度' (Subsidiary Management System) issued by 广州市香雪制药股份有限公司. It details internal management rules and procedures for subsidiaries, including governance, financial management, investment, information disclosure, internal audit, and personnel management. There are no financial statements, earnings data, or regulatory filings. The document is a corporate governance and internal control policy document rather than a report or announcement. It does not fit into categories like Annual Report, Interim Report, or Audit Report. It is a governance-related document describing company internal rules and board oversight of subsidiaries. Therefore, the most appropriate classification is Governance Information (CGR). The document length is about 4895 characters, which is sufficient for a substantive policy document, not a brief announcement.
2025-11-28 Chinese
独立董事工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System' and contains detailed rules and procedures regarding the roles, responsibilities, nomination, election, and duties of independent directors within the company. It references relevant laws, regulations, and governance codes, and outlines governance practices related to board structure and director duties. There is no financial data, earnings information, or report publication announcement. The content is focused on governance and internal rules for board members, specifically independent directors. Therefore, this document fits the category of Governance Information (CGR). The document length (6841 characters) and detailed procedural content support this classification with high confidence.
2025-11-28 Chinese
第九届董事会第三十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from 广州市香雪制药股份有限公司 regarding the approval of the 2025 third quarter report. It states that the report's preparation complies with legal requirements and that the report is available on an external website (巨潮网). The document itself does not contain the full quarterly report or substantive financial data but rather announces the board's approval of the report and directs readers to the full report elsewhere. The document length is short (663 characters), and it serves as an announcement of the report rather than the report itself. Therefore, it fits the category of Regulatory Filings (RNS) as a general regulatory announcement about the report approval, not the full Interim/Quarterly Report (IR).
2025-10-27 Chinese
第九届监事会第二十二次会议决议公告
Report Publication Announcement Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the approval of the company's 2025 third quarter report. It states that the Supervisory Board reviewed and approved the full 2025 third quarter report, confirming its accuracy and compliance. However, the document itself does not contain the actual financial data or the full report, but rather refers to the full report being disclosed on another platform (Juchao website). The document length is short (581 characters) and serves as an announcement of the approval and existence of the report, not the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the Interim/Quarterly Report (IR) itself.
2025-10-27 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "广州市香雪制药股份有限公司2025 年第三季度报告" which translates to "Guangzhou Xiangxue Pharmaceutical Co., Ltd. 2025 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics for the third quarter of 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the period. It also mentions that the report is unaudited, which is common for interim or quarterly reports. The length of the document (12,626 characters) and the detailed financial content confirm it is the actual report, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2025
2025-10-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.